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What is the efficacy of viral and bacterial vaccines in feedlot cattle to
reduce bovine respiratory disease (BRD) and subsequent antibiotic use?
Abstract
Bovine respiratory disease complex is the most economically significant disease of feedlot cattle[4]. Putative
causal organisms include Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and
Mycoplasma bovis, bovine herpesvirus, bovine viral diarrhea virus, bovine respiratory syncytial virus, and
parainfluenza type 3 virus[5].
Vaccination against the putative causal organisms is a frequently used approach to aid in the prevention of
BRD. With a more significant concern for prudent antibiotic use in the beef industry, it is vital that decision
making with regards BRDC management be based on an understanding of the efficacy of vaccination
programs and management factors that might modify the efficacy of the preventive management practice[6,
7]. Systematic reviews of randomized controlled trials yield the highest level of evidence for the efficacy of
treatment under field conditions, and comparative efficacy can be examined using network meta-analysis for
multiple comparisons. Establishing the efficacy of monovalent and polyvalent vaccinations for the prevention
of BRDC in feedlot cattle will serve to improve decision makers’ ability to engage in effective stewardship of
antibiotics.
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1 Introduction.  
PRISMA-P ITEM 6 Rationale”  
Bovine respiratory disease complex is the most economically significant disease of feedlot cattle[4].  
Putative causal organisms include Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and 
Mycoplasma bovis, bovine herpesvirus, bovine viral diarrhea virus, bovine respiratory syncytial virus, and 
parainfluenza type 3 virus[5].    
Vaccination against the putative causal organisms is a frequently used approach to aid in the prevention of 
BRD. With a more significant concern for prudent antibiotic use in the beef industry, it is vital that decision 
making with regards BRDC management be based on an understanding of the efficacy of vaccination 
programs and management factors that might modify the efficacy of the preventive management practice[6, 
7]. Systematic reviews of randomized controlled trials yield the highest level of evidence for the efficacy 
of treatment under field conditions, and comparative efficacy can be examined using network meta-analysis 
for multiple comparisons. Establishing the efficacy of monovalent and polyvalent vaccinations for the 
prevention of BRDC in feedlot cattle will serve to improve decision makers’ ability to engage in effective 
stewardship of antibiotics. 
PRISMA-P ITEM 7 Objectives:   
The objective of this protocol is to describe a systematic review to address the efficacy of vaccination 
against putative organisms for BRDC. The specific review questions to be addressed in this protocol are as 
follows: 
What is the efficacy of bacterial and viral vaccines (alone or in combination) administered at arrival to 
prevent BRDC in feedlot cattle? The specific PICO elements, which will define the eligibility criteria, are 
as follows: 
x Population: Weaned cattle raised for meat in intensive systems at risk of BRDC  
x Intervention: Commercially available in any country viral and/or bacterial vaccines used alone or 
in combination 
x Comparator:  placebo, different vaccination regime, or no treatment. 
x Outcomes:  Critical outcomes will be the cumulative incidence of first-treatment rate for BRDC in 
the first 45 days of the feedlot period. Secondary outcomes will be the cumulative incidence of 
first-treatment rate BRDC in the entire feedlot period and second-treatment rate for BRDC 
2 Methods 
PRISMA-P ITEM 8 Eligibility criteria:   
In addition to eligibility criteria as described in the PICO elements above, eligibility criteria will include 
publication in English. Both published and non-published (grey literature) studies are eligible, provided 
they report a primary research study with a concurrent comparison group using an eligible study design. 
Controlled trials (i.e., with a concurrent control group) conducted in feedlot settings (groups of cattle 
penned receiving rations, i.e., not grazing), cluster–randomized controlled trials (C-RCT), or individually 
randomized controlled trials (I-RCT) are eligible.  
PRISMA-P ITEM 9 Information sources:   
We will conduct the literature search in a range of relevant bibliographic databases and other information 
sources containing both published and unpublished literature. Error! Reference source not found.1 
presents the resources to be searched.  
Table 1: Databases and information sources to be searched 
Database / information source Interface / URL 
MEDLINE®, MEDLINE In-Process and MEDLINE®  Daily Epub 
Ahead of Print 
Ovid SP  
CAB Abstracts  (via Web of 
Science)  
Science Citation Index  (via Web of 
Science)  
Conference Proceedings Citation Index – Science (via Web of 
Science)  
Agricola Proquest 
We will also hand-search the table of contents of the following relevant conferences from 1997 to 2018: 
x Proceedings of the American Association of Bovine Practitioners; 
x World Association for Buiatrics; 
PRISMA-P ITEM 10 Search strategy:   
A Science Citation Index (Web of Science) search strategy designed to identify studies on the efficacy of 
viral and bacterial vaccines in feedlot cattle to reduce bovine respiratory disease (BRD) is presented in  
Table 2 
The search strategy employs three concepts:  
• Beef cattle   
AND  
• BRD, or the viruses and bacteria known to cause BRD  
AND 
Vaccination  
The search is structured so that the searches for viral vaccines are performed separately to those for bacteria 
vaccines within a single strategy.  This is because an existing 2015 systematic review assessed the efficacy 
of commercially available viral vaccines for mitigation of the effects of bovine respiratory disease 
complex.[6] A conceptual breakdown of  
beef cattle AND (BRD OR BRD viruses) AND vaccination 
is therefore limited to studies published from 2014 to current in order to update this review (Figure 1, line 
11).  
Bacterial vaccines are captured with the following conceptual breakdown that is unlimited by date (Figure 
1, line 16).  
beef cattle AND BRD bacteria AND vaccination 
The results of both the viral and bacterial searches are combined in line 17 to give a total number of records 
for all vaccines.  
Table 2: Search strategy to identify studies on the efficacy of viral and bacterial vaccines in 
feedlot cattle to reduce bovine respiratory disease (BRD) in Science Citation Index (Web of 
Science) All search except #11 are Indexes=SCI-EXPANDED Timespan=All years 
# 17 #16 OR #11 1,177 
# 16 #15 AND #9 AND #1 724  
# 15 #14 OR #13 OR #12 27,864 
# 14 TS=("pasteurella multocida" OR "p multocida" OR 
"mycoplasma") 
25,456 
# 13 TS=("haemophilus somn*" OR "hemophilus somn*" OR 
"histophilus somn*" OR "h somnus" OR "h somni") 
606 
# 12 TS=("mannheimia haemolytica" OR "mannheimia hemolytica" 
OR "m haemolytica" OR "m hemolytica" OR "pasteurella 
haemolytica" OR "pasteurella hemolytica" OR "p haemolytica" 
OR "p hemolytica" OR mannheimios*) 
2,525 
# 11 #10 (Indexes=SCI-EXPANDED Timespan=2014-2018) 563 
# 10 #9 AND #8 AND #1 3,219  
# 9 TS=(vaccin* OR immunis* OR immuniz* OR innoculat*) 351,581 
# 8 #7 OR #6 OR #5 OR #4 OR #3 OR #2 284,032 
# 7 TS=("parainfluenza3" OR "influenza3" OR "parainfluenza 3" OR 
"influenza 3" OR "parainfluenza three" OR "influenza three" OR 
"parainfluenza type 3" OR "influenza type 3" OR "parainfluenza 
type three" OR "influenza type three" OR "PI-3" OR "PI3") 
17,417 
# 6 TS=("respiratory syncytial virus*" OR "BRSV" OR "RSV") 19,370 
# 5 TS=("BVD" OR "BVDV" OR "BVDV1" OR "BVDV2" OR 
"pestivirus" OR "coronavirus" OR "BCV") 
15,842 
# 4 TS=(("viral" OR "virus" OR "viruses") NEAR/3 (diarrhoea* OR 
diarrhea*)) 
6,386 
# 3 TS=(herpesvirus* OR "herpes virus*" OR herpesviridae* OR 
"herpes viridae*" OR "BoHV-1" OR "BoHV1" OR "BHV-1" OR 
"BHV1" OR "BHV" OR "BoHV" OR "rhinotracheitis" OR 
"rhinotracheitides" OR "IBRV" OR "IBR") 
37,021 
# 2 TS=("respiratory disease*" OR "respiratory tract disease*" OR 
"respiratory virus*" OR "respiratory tract virus*" OR "shipping 
fever" OR "undifferentiated fever" OR "BRD" OR "BRDC" OR 
"pasteurellosis" OR pneumonia* OR pleuropneumonia* OR 
"pneumonitis" OR "pneumonitides") 
201,492 
# 1 TS=("cow" OR "cows" OR "cattle" OR heifer* OR "steer" OR 
"steers" OR "bull" OR "bulls" OR "calf" OR "calves" OR 
524,340 
"youngstock*" OR "young-stock*" OR "beef" OR "veal" OR 
"bovine" OR "bovinae" OR buiatric*) 
 
The search strategies will not be limited by date, language, or publication type. We will conduct searches 
using each database listed in the protocol, translating the agreed strategy appropriately to reflect the 
differences in database interfaces and functionality. We will document all search strategies and search 
results, and we will provide this in the final report to meet standard requirements for clear and formal 
reporting of the search process 
PRISMA-P ITEM 11 Study records: 
 Data management:  We will download the results of searches in a tagged format and load them into 
bibliographic software (EndNote). The results will be deduplicated using several algorithms and the 
duplicate references held in a separate EndNote database for checking if required. We will save results from 
resources that do not allow export in a format compatible with EndNote in Word or Excel documents as 
appropriate and manually deduplicate. The de-duplicated search results from EndNote will be uploaded 
into online systematic review software (DistillerSR®, Ottawa, ON, Canada). Reviewers will have training 
in epidemiology and systematic review methods. Before both abstract and full-text screenings, data 
extraction, and risk of bias assessment, the reviewers assigned to each step will undergo training to ensure 
consistent data collection using the forms created in DistillerSR®.  
Selection process:  In the first round of screening, abstracts and titles will be screened for inclusion. Two 
reviewers will independently evaluate each citation for relevance using the following questions: 
1) Does the study involve assessment of vaccines for the prevention of bovine respiratory disease in feedlot 
cattle?  
x Yes/Unclear- next question 
x No –exclude 
2) Is there a concurrent comparison group? (i.e., controlled trial with natural or deliberate disease exposure 
or analytical observational study)? 
x Yes/Unclear- include for full-text assessment 
x No –exclude 
Citations will be excluded if both reviewers responded “no” to any of the questions. If one reviewer says 
yes, the citation will move to full-text assessment. A pre-test will be conducted by all reviewers on the first 
100 abstracts to ensure clarity of questions and consistency of understanding of the questions. Following 
title/abstract screening, eligibility will be assessed through full-text screening.   Two reviewers will 
independently evaluate the full-text articles, with any disagreements resolved by consensus. If consensus 
cannot be reached, a third reviewer will be used. 
1) Correct population: Is the study population, weaned calves in a non-grazing situation with naturally 
occurring BRDC, i.e., feedlot cattle?  
x Yes- Next question 
x No –exclude 
2) Correct Interventions and Comparator: Does the study assess the use of a commercially available 
monovalent or polyvalent vaccine for one of the following organisms (Mannheimia haemolytica, 
Pasteurella heamolytica, Pasteurella multocida, Histophilus somni or Mycoplasma bovis, bovine 
herpesvirus, bovine viral diarrhea virus, bovine respiratory syncytial virus, and parainfluenza type 3 virus)? 
x Yes- Next question 
x No –exclude 
3) Correct outcome: Does the study report the risk of BRDC in the study groups? 
x Yes- Next question 
x No- exclude 
4) Correct study design: Is the study a field trial (where an investigator is allocating animals to the group) 
with naturally occurring BRDC? 
x Yes- include in data extraction  study  
x No –Challenge study (indicate the  organism(s) studied) 
x No - Observational study (the investigator did not allocate to the group – allocation was 
chosen by producers or owner, indicate the organism studies) 
Data collection process: Data will be extracted by two reviewers working independently. Consensus will 
resolve any disagreements or, if consensus cannot be reached, a third reviewer will be used.  Authors will 
not be contacted to request missing data or to clarify published results. A form for data extraction will be 
created for this review in DistillerSR® and pre-tested on 4 full-text articles to ensure question clarity. 
PRISMA-P ITEM 12 Data items:   
Study-level data to be collected: 
x Country 
x Location 
x Year of conduct 
x Breed 
x Age (entire group or control group data if provided) 
x Weight (entire group or control group data if provided) 
x Definition of BRDC 
x No of animals eligible for study 
x Unit of allocation (Cluster (pen) or individual)  
x Approach to allocation 
Arm-level data to be collected: 
x Vaccine name – as reported by investigators 
x Target organism(s) 
x Dose/ Route/ Frequency of administration 
x Timing of vaccination compared to arrival 
x Number of animals enrolled 
x Number of animals lost to follow up 
x Number of animals analyzed 
x Number of clusters for C-RCT 
x For C-RCT, the approach to the analysis of non-independent observations i.e., not reported, 
"multilevel model", a "variance components analysis" or may use "generalized estimating 
equations" (GEEs), among other techniques. 
x For non-randomized studies, the information extracted will be the antibiotic label dose regime and 
trade names used for the study. This information will be most useful when deciding what, if any 
important , studies had been conducted using a non-randomized trial.  
PRISMA-P ITEM 13 Outcomes and prioritization:   
For the primary outcome of interest, risk of BRDC in the first 60 days, we will extract in the following 
order of possible metrics: 
For C-RCT and I-RCT  
x 1st priority: Adjusted summary effect size (adjusted risk ratio or adjusted odds ratio), variables included 
in adjustment, precision estimate and variance components estimatesf for C-RCTs. 
x 2nd priority: Unadjusted summary effect size and corresponding precision estimate  
x 3rd priority: Arm-level risk of BRDC 
Prioritization means we will not collected the additional metrics if the prioritized metric of reported. The 
rationale for the prioritzation is that the meta-analysis should use an adjusted summary effect for most of 
these studies. Although we expect that many will be I-RCTand therefore the other metrics will require 
conversion to the summary effect.    
x The secondary outcomes are first-treatment rate of BRDC in the entire feedlot period and second-
treatment rate for BRDC, and we will prioritize the same metrics. 
PRISMA-P ITEM 14 Risk of bias in individual studies:   
Risk of bias will only be assessed for controlled trials with natural disease exposure. Risk-of-bias 
assessment will be performed at the outcome level for each of the critical outcomes using the Cochrane risk 
of bias instrument, with the signaling questions modified as necessary for the specific review question. The 
ROB 2.0 for clustered –RCT and individual RCTs will be used depending upon the study design [8]. These 
tools are available at https://sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool.  
PRISMA-P ITEM 15 Data synthesis:  
Network meta-analysis. Network meta-analysis (aka mixed treatment comparison meta-analysis) will use 
the approach described by NICE Decision Support Unit technical document The approach to reporting will 
use the PRISMA- NMA (http://www.prisma-statement.org/Extensions/NetworkMetaAnalysis.aspx)[9-14].  
For cluster-randomized trials, it will be necessary to verify that the potential for a unit-of-analysis error did 
not bias the estimate of precision. When the unit of analysis was not adjusted, we will use the approach 
previously proposed to adjust for non-independent observations.  If network meta-analysis can not be 
conducted due to spare data we will conduct pairwise meta-analyses.  
PRISMA-P ITEM 16 Meta-bias(es):  
Small-study effects (“publication bias”) will be assessed for all vaccine-comparator combinations, where 
there are at least ten studies in the meta-analysis, using funnel plots[15, 16]. If feasible, we will use 
approaches to assessing publication bias in the network of evidence using previously proposed approaches .  
PRISMA-P ITEM 17 Confidence in cumulative evidence:   
The quality of evidence for each critical outcome will be assessed using the approach proposed by GRADE 
[17, 18]while also considering the nature of the network meta-analysis. 
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